Inymel Biomedica S.L.
Inymel (IMB) is a clinical-stage biotech company developing first-in-class melatonin treatments.
This information is confidential, do not share or copy.
You can visit their website or
Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19 - Frontiers in Medicine Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 - Nature COVID-19: Melatonin as a potential adjuvant treatment - ScienceDirect
Under evaluation at least till: 7th June
KEEP REVIEWING